Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10651515 | 0.88 | ALOX15 (0.44) | ALOX15HIF1AEPAS1LMNACYP3A4 | |
| SCHEMBL3358285 | 0.86 | ALOX15 (0.47) | ALOX15HIF1AEPAS1LMNACYP3A4 | |
| SCHEMBL3360768 | 0.78 | ALOX15 (0.50) | ALOX15HIF1AEPAS1LMNACYP3A4 | |
| SCHEMBL8743652 | 0.77 | ALOX15 (0.52) | ALOX15HIF1AEPAS1LMNACYP3A4 | |
| SCHEMBL2687438 | 0.77 | ALDH1A1 (0.34) | LMNAALDH1A1GAA | |
| SCHEMBL9576614 | 0.76 | ALOX15 (0.48) | ALOX15HIF1AEPAS1LMNACYP3A4 | |
| SCHEMBL14323431 | 0.71 | ALOX15 (0.48) | ALOX15HIF1AEPAS1LMNACYP3A4 | |
| SCHEMBL3358291 | 0.71 | ALOX15 (0.44) | ALOX15ALDH1A1BTN3A1 | |
| SCHEMBL3749023 | 0.71 | ALOX15 (0.45) | ALOX15HIF1AEPAS1LMNACYP3A4 | |
| SCHEMBL609524 | 0.70 | LMNA (0.40) | LMNACYP3A4ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781522-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUND, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND USING SAID CATALYST | Sumitomo Chemical Company, Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-7705165-B2 | Method for producing optically active cyclopropanecarboxylate compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-27 | — | — | US | disclosed |
| US-20080027235-A1 | Method for Producing Optically Active Cyclopropanecarboxylate Compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027235-A1 | Method for Producing Optically Active Cyclopropanecarboxylate Compound | ACSL6, AOC1, CA6 | ALOX15 593/4885HIF1A 3385/4885EPAS1 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.